Seat­tle Ge­net­ics, Gen­mab turn on TV for a high­light reel in cer­vi­cal can­cer — but a ri­val biotech promis­es a bet­ter show

Seat­tle Ge­net­ics $SGEN and their part­ners at Gen­mab $GMAB pol­ished up some pos­i­tive Phase II num­bers for their an­ti­body drug con­ju­gate ti­so­tum­ab ve­dotin — you can call it TV — for re­cur­rent cer­vi­cal can­cer. And while they mapped out a short­cut to a po­ten­tial quick ap­proval, the big chal­lenge for this team is be­ing pre­sent­ed by a ri­val biotech which mus­cled its way in­to the spot­light for the same in­di­ca­tion a year ago.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER